Given that the exchange-traded fund industry moves fast in trying to cash in on the newest “It” theme or trend, it was only a matter of time before a company would devise a product tied to the coronavirus pandemic.

As such, Pacer ETFs this week filed for registration with the Securities and Exchange Commission for the Pacer BioThreat ETF, which comes with the appropriately catchy ticker VIRS.

The VIRS fund tracks the BioShares BioThreat Index targeting U.S.-listed stocks of companies that help protect against—or recover from—biological threats to human health.

According to the registration statement, index provider LifeSci Index Partners LLC employs fundamental research to identify the most important current and emerging biological threats to human health including pandemic diseases, biological warfare, food and water safety, environmental safety and natural disasters.

Then it scours publicly available information such as financial reports and screens, corporate websites, news reports and interviews with key people in this broad space to identify publicly traded companies with products, technologies and services that, among things, “combat pandemic diseases such as the novel coronavirus (COVID-19), Zika, H1N1, Ebola, avian flu, and MERS.”

Other focus areas among the index constituents include combatting agents of biological or chemical warfare such as anthrax, sarin gas, variola virus (smallpox and other poxes) and brucellosis.

Index components from the health-care and industrial sectors must have a minimum market capitalization of $1 billion and a minimum average daily value traded for the prior six months of at least $2 million. The index is market-cap weighted, and individual holdings are capped at 4.9% at semi-annual rebalancing.

No fund fee information was provided.

Pacer ETFs has 22 products with roughly $5.1 billion in assets under management.